An immunological storm for cancer therapy: 2018 Nobel Prize in Physiology or Medicine

• 来源期刊: 科学通报（英文版）
• 年，卷（期）: 2018,（24）
• 页码范围: 1608-1610
• 页数: 3页
• 语种: 英文

摘要

Immunotherapy with checkpoint inhibitors (CPIs) is a new approach to cancer therapy that harnesses and enhances the innate abilities of the immune system to recognize and fight cancers.It has become a breakthrough in the history of cancer treatment and is of epoch-making significance [1]. In the past century,Nobel Prize has been awarded to the advances in immunology for 15 times.This year,it won for the 16th time.James P.Allison from the University of Texas MD Anderson Cancer Center and Japanese immunologist Tasuku Honjo were awarded the 2018 Nobel Prize in Physiology or Medicine,for their great contributions to the discovery of the CTLA-4 and PD-1 and the development of promising cancer therapy by inhibition of negative immune regulation.Their research shows how different strategies to inhibit the brakes on the immune system can be used in the treatment of cancer,which became a landmark in the history of cancer therapy.